Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Combination of ENaC and CFTR mutations may predispose to cystic fibrosis-like disease

I. Fajac, M. Viel, N. Gaitch, D. Hubert, T. Bienvenu
European Respiratory Journal 2009 34: 772-773; DOI: 10.1183/09031936.00057309
I. Fajac
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Viel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. Gaitch
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Hubert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. Bienvenu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

To the Editors:

The epithelial sodium channel (ENaC) is part of the complex protein cystic fibrosis transmembrane conductance regulator (CFTR)-interactome that plays a key role in the composition of the airway surface liquid and the mucociliary clearance in the airways. We have recently screened ENaC beta and gamma genes in 55 patients with diffuse bronchiectasis and with only one or no CFTR mutation/variant and showed that eight (15%) patients carried at least one missense mutation in these ENaC genes 1. Azad et al. 2 have also investigated the frequency of ENaC mutations in ENaC alpha, beta and gamma genes in a cohort of 76 patients with cystic fibrosis (CF)-like disease and with only one or no mutation in the CFTR gene. They found a significant increase in missense mutations or variants in patients (15.3%) compared with controls (8.9%) 2. Moreover, a variant in ENaC alpha gene called p.W493R was found at a more than two-fold significantly increased incidence in patients (8%) compared with controls (3%) and, in the Xenopus laevis oocyte expression system, p.W493R was found to result in a more than four-fold higher ENaC activity.

We recently completed our previous study by screening exons and flanking intronic sequences of ENaC alpha gene in the previously studied 55 patients (13 males and 42 females) with diffuse idiopathic bronchiectasis and with only one or no CFTR mutation/variant. We found three different intronic sequence variations (c.1242+54C>T, c.1553+32G>A and c.1554-6C>T) that are believed to be not deleterious and two different amino acid changes in heterozygous state in three patients of Caucasian origin: p.V462I in one patient and the p.W493R mutation extensively studied by Azad et al. 2 in two patients. One of those also carried one CFTR variant (IVS8-5T) and one mutation in ENaC beta gene (p.S82C). The main results from these three patients are summarised in table 1⇓.

View this table:
  • View inline
  • View popup
Table 1—

Main characteristics of the three patients with idiopathic bronchiectasis bearing a missense mutation inENaC alpha gene

It has been shown that the common human ENaC alpha polymorphism hαA663T is a functional polymorphism that affects human ENaC surface expression, with lower channel activity and lower apparent number of active channels 3, 4. Therefore, we studied the distribution of the hαA663T genotypes in our group of 55 patients with diffuse bronchiectasis. We did not observe a significant increase in the presence of the hαA663T genotype in our group (A663 allele; 69%) compared with the expected frequency in controls (58–70.8%) 2, 5.

To summarise the results from our 55 patients with bronchiectasis, 10 (18%) patients carried at least one missense mutation in the ENaC alpha (as outlined in this report), beta or gamma genes 1. Among them, six had evidence of abnormal sodium transport, either in the sweat glands (sweat chloride concentration 40–59 mmol·L−1) or in the nasal epithelium (basal nasal potential difference (PD) magnitude >30 mV or <10 mV). Interestingly, three patients were transheterozygotes for CFTR/ENaC mutations or variants: they carried either the p.F508del mutation or the IVS8-5T variant of the CFTR gene and all carried the p.S82C mutation in ENaC beta gene; one of them also carried the p.W493R mutation in ENaC alpha gene (table 1⇑). The basal PD in this patient was normal (-13 mV) and no pharmacological study was performed. However, her sweat test was intermediate (44 mmol·L−1) showing that the combination of the CFTR variant and the ENaC mutations led to functional abnormalities.

Given the CF carrier incidence of ∼3.3% (one out of 30) and the 5T carrier incidence of ∼10%, and the fact that ∼9% of the individuals in the general population is expected to carry a rare ENaC mutation, about one in 334 (0.30%) of individuals are expected to be heterozygous for both a CF-causing CFTR mutation/variant and ENaC missense mutation 2, 6, 7. In 55 patients with diffuse bronchiectasis of unknown origin, we found an unexpected high proportion (5%) of heterozygosity for both a CF-causing CFTR mutation/variant and ENaC mutation. Mutesa et al. 8 recently showed that, among five Rwandan patients with CF-like symptoms, elevated sweat chloride and with only one CFTR mutation identified, two of them carried one missense mutation in the ENaC genes. Taken together, these results suggest that transheterozygosity for ENaC/CFTR mutations or variants may lead to deficient ENaC/CFTR interaction, and abnormal ion transport in the airways and bronchiectasis.

Statement of interest

None declared.

    • © ERS Journals Ltd

    References

    1. ↵
      Fajac I, Viel M, Sublemontier S, et al. Could a defective epithelial sodium channel lead to bronchiectasis. Respir Res 2008;9:46–53.
      OpenUrlCrossRefPubMed
    2. ↵
      Azad AK, Rauh R, Vermeulen F, et al. Mutations in the amiloride-sensitive epithelial sodium channel in patients with cystic fibrosis-like disease. Hum Mutat 2009;30:1093–1103.
      OpenUrlCrossRefPubMedWeb of Science
    3. ↵
      Samaha FF, Rubenstein RC, Yan W, et al. Functional polymorphism in the carboxyl terminus of the α-subunit of the human epithelial sodium channel. J Biol Chem 2004;279:23900–23907.
      OpenUrlAbstract/FREE Full Text
    4. ↵
      Tong Q, Menon AG, Stockand JD. Functional polymorphisms in the α-subunit of the human epithelial Na+ channel increase activity. Am J Physiol Renal Physiol 2006;290:F821–F827.
      OpenUrlAbstract/FREE Full Text
    5. ↵
      Sugiyama T, Kato N, Yamori Y, et al. Evaluation of selected polymorphisms of the mendelian hypertensive disease genes in the Japanese population. Hypertens Res 2001;24:515–521.
      OpenUrlCrossRefPubMedWeb of Science
    6. ↵
      Des Georges M, Guittard C, Altieri JP, et al. High heterogeneity of CFTR mutations and unexpected low incidence of cystic fibrosis in the Mediterranean France. J Cyst Fibros 2004;3:265–272.
      OpenUrlCrossRefPubMed
    7. ↵
      Chillon M, Casals T, Mercier B, et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med 1995;332:1475–1480.
      OpenUrlCrossRefPubMedWeb of Science
    8. ↵
      Mutesa L, Azad AK, Verhaeghe C, et al. Genetic analysis of Rwandan patients with cystic fibrosis-like symptoms: identification of novel cystic fibrosis transmembrane conductance regulator and epithelial sodium channel gene variants. Chest 2009;135:1233–1242.
      OpenUrlCrossRefPubMedWeb of Science
    View Abstract
    PreviousNext
    Back to top
    View this article with LENS
    Vol 34 Issue 3 Table of Contents
    European Respiratory Journal: 34 (3)
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Combination of ENaC and CFTR mutations may predispose to cystic fibrosis-like disease
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Citation Tools
    Combination of ENaC and CFTR mutations may predispose to cystic fibrosis-like disease
    I. Fajac, M. Viel, N. Gaitch, D. Hubert, T. Bienvenu
    European Respiratory Journal Sep 2009, 34 (3) 772-773; DOI: 10.1183/09031936.00057309

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    Combination of ENaC and CFTR mutations may predispose to cystic fibrosis-like disease
    I. Fajac, M. Viel, N. Gaitch, D. Hubert, T. Bienvenu
    European Respiratory Journal Sep 2009, 34 (3) 772-773; DOI: 10.1183/09031936.00057309
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • Statement of interest
      • References
    • Figures & Data
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • How can we achieve better prevention of TB among contacts?
    • Predictors of treatment outcome in MDR-TB in Portugal
    • Drug concentration in lung tissue in MDR-TB
    Show more Letters

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERJ

    • Journal information
    • Editorial board
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Publication ethics and malpractice
    • Submit a manuscript

    For readers

    • Alerts
    • Subjects
    • Podcasts
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN:  0903-1936
    Online ISSN: 1399-3003

    Copyright © 2023 by the European Respiratory Society